Gynecological cancer trial groups represented in European Network of Gynecological Oncological Trial Groups Study group (country) AGO – Austria, Arbeitsgemeinschaft Gynäkologische Onkologie Austria AGO Study Group, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe,…
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_14 14. Clear Cell Carcinoma Masashi Takano1 , Satoshi Takakura2 and Keiichi Fujiwara3 (1) Department of Clinical Oncology, National Defense Medical College Hospital, 3-2 Namiki, Tokorozawa Saitama, 359-8513,…
Fig. 11.1 The major T cell-based immunotherapeutic targets and their tumor or antigen-presenting cell ligands. The activation of T cells and their conversion to a cytotoxic phenotype is governed by…
PARP inhibitor Company PARP inhibition Details Olaparib (AZD2281) AstraZeneca PARP 1/2/3 Licensed in EU for maintenance BRCAm; ≥3rd line (FDA) in BRCAm. Phase III trials with tablet formulation – first…
Fig. 2.1 BRCA, DNA repair and the cell cycle (Foulkes and Shuen [9]). In response to DNA damage, BRCA1 mediates HR (depicted in the outer ring) and cell cycle regulation…
Gene mutation Serous tumor of LMP Low-grade serous carcinoma References TP53 0–8 % 0–8.3 % [30, 82] KRAS 33–61.8 % 19–41 % [11, 31, 82, 108] BRAF 14.5–28 % 2–33…
Fig. 10.1 Criteria for decision making When Should the Relapse Be Treated? In most of cases, CA 125 elevation is the first signal of recurrence; it can be observed some…
Items Possible responses (score) A Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties? 0 = severe decrease…
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_8 8. First-Line Systemic Therapy (Chemo/Antiangiogenics) Sandro Pignata1 and Sabrina Chiara Cecere1 (1) Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G…
NCT# Name Type – site Objective MRI NCT02243059 MILO Maastricht University Medical Center Magnetic resonance imaging for lymph node staging in ovarian cancer NCT02334371 Maastricht University Medical Center MR-PET for…
